Skip to main content

Table 3 Unadjusted and adjusted odds ratios for predictors of persistent high-risk (hr) human papillomavirus (HPV) infection (n = 71)

From: Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark – the SHADE

Predictors of persistence HrHPV Persistence (n = 31) HrHPV Clearance (n = 40) Unadjusted odds ratios p-value Adjusted odds ratiosa, b p-value
Age when first hrHPV positive, n(%)
  ≥ 35 years 22 (44.9) 27 (55.1) 1.00 1.00
 18–34 years 9 (40.9) 13 (59.1) 0.85 (0.31–2.36) 0.75 0.52 (0.13–2.07) 0.35
 (missing) (0) (0)     
Race, n(%)
 White 13 (39.4) 20 (60.6) 1.00 1.00
 Asian 4 (80.0) 1 (20.0) 6.15 (0.62–61.37) 0.12 7.38 (0.68–80.17) 0.10
 Black 14 (45.2) 17 (54.8) 1.27 (0.47–3.42) 0.64 1.71 (0.52–5.64) 0.38
 (missing) (0) (2)     
 Combined p-value     0.30   0.22
ART duration, (years)
 Median (IQR) 5.4 (3.3–11.4) 8.1 (2.6–12.1) 0.97 (0.88–1.07) 0.52 0.91 (0.80–1.04) 0.17
 (missing) (1) (3)     
AIDS prior to inclusion, n(%)
 No 21 (38.9) 33 (61.1) 1.00 1.00
 Yes 10 (62.5) 6 (37.5) 2.62 (0.83–8.28) 0.10 3.77 (0.99–14.38)  
 (missing) (0) (1)     0.05
Smoking status, n(%)
 Never smoker 17 (43.6) 22 (56.4) 1.00 1.00  
 Current smoker/ Ex-smoker 14 (43.8) 18 (56.2) 1.01 (0.39–2.58) 0.99 1.13 (0.35–3.68) 0.84
 (missing) (0) (0)     
CD4 count when first hrHPV positive (cells/μL), n(%)
  ≥ 350 16 (36.4) 28 (63.6) 1.00 1.00  
 350 11 (68.8) 5 (31.2) 3.85 (1.13–13.07) 0.03 4.36 (1.18–16.04) 0.03
 (missing) (4) (7)     
  1. ART = combined antiretroviral therapy
  2. aThe validity of the model was tested using the Hosmer and Lemeshow Goodness-of-Fit Test, bDuration of ART, AIDS prior to inclusion and CD4 count are dependent covariates and where calculated using two models: A model where all variables, but CD4 at inclusion were included and a model where duration of ART and AIDS prior to inclusion were replaced by CD4. We only present the OR of the CD4 count from the second model